Readership
Bioengineers, Biologists, Cell Biologists, Clinicians, Cytologists, Healthcare Executives, Molecular Biologists, Pharmacologists, Researchers, Technologists
Scope
Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and ‘omic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape the future of medicine by providing a platform for expert commentary and analysis.
The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles. Articles submitted to Personalized Medicine are subject to rigorous peer review. Topics addressed include:
Implementation of genomics in medicine, Advances in molecular diagnostics, Biochip/microarray technologies, Impact of precision medicine strategies on drug development, Impact of precision medicine strategies on health care delivery, Developing the evidence basis for adoption of precision medicine, National sequencing programs, Impact of the latest concepts of development of precision medicine based on pharmacogenomics, pharmacogenetics and pharmacoproteomics, Integration of diagnosis with therapy, Prediction of adverse reactions of drugs and drug safety, Treatment monitoring, Therapeutic applications of genome editing and associated technologies, Ethical, Legal and Social issues in personalized medicine, Educational strategies/workforce development for precision medicine, Information technology strategies and precision medicine, Participant and patient engagement for precision medicine, Data science and data analytics for precision medicine, Digital health and precision medicine, Cost-benefit and economic outcomes for precision medicine.